Showing results (261-270 of 569) with videos related to
Sort By:
Pageof 57
JAMA|September 3, 2010
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortalitySusan M Domchek, Tara M Friebel, Christian F Singer, et al.NPJ Breast Cancer|October 24, 2025
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trialAndrea E Wahner Hendrickson, Karen S Flatten, Taylor M Weiskittel, et al.Breast Cancer Research and Treatment|December 19, 2023
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCYJudith Balmaña, Peter A Fasching, Fergus J Couch, et al.Frontiers in Oncology|June 14, 2024
Blockade of tumor cell-intrinsic PD-L1 signaling enhances AURKA-targeted therapy in triple negative breast cancerAndrew Takchi, Minzhi Zhang, Mohammad Jalalirad, et al.Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|June 26, 2025
Assessing hospital antibiotic stewardship program (ASP) implementation: validation of an implementation science-informed surveyJorie Michaela Butler, Ellen Childs, Tamar Barlam, et al.JCO Precision Oncology|August 25, 2020
Pathogenic Variants in Cancer Predisposition Genes and Prostate Cancer Risk in Men of African AncestryMarco Matejcic, Yesha Patel, Jenna Lilyquist, et al.Human Mutation|December 16, 2020
Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancerPaula S Felicio, Rebeca S Grasel, Natalia Campacci, et al.Nature|January 8, 2025
Functional evaluation and clinical classification of BRCA2 variantsHuaizhi Huang, Chunling Hu, Jie Na, et al.Journal for Immunotherapy of Cancer|June 3, 2026
Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancerYi Liu, Jodi M Carter, Yaohua Ma, et al.JAMA Oncology|February 29, 2024
MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJan Lubinski, Joanne Kotsopoulos, Pal Moller, et al.Pageof 57